- Home
- LUNG vs SERA Comparison
LUNG vs SERA Comparison
Compare LUNG & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUNG
- SERA
- Stock Information
- Founded
- LUNG 1995
- SERA 2008
- Country
- LUNG United States
- SERA United States
- Employees
- LUNG N/A
- SERA N/A
- Industry
- LUNG Industrial Specialties
- SERA Precision Instruments
- Sector
- LUNG Health Care
- SERA Health Care
- Exchange
- LUNG Nasdaq
- SERA Nasdaq
- Market Cap
- LUNG 248.0M
- SERA 258.3M
- IPO Year
- LUNG 2020
- SERA 2021
- Fundamental
- Price
- LUNG $7.30
- SERA $7.21
- Analyst Decision
- LUNG Strong Buy
- SERA
- Analyst Count
- LUNG 7
- SERA 0
- Target Price
- LUNG $13.71
- SERA N/A
- AVG Volume (30 Days)
- LUNG 240.7K
- SERA 140.4K
- Earning Date
- LUNG 10-28-2024
- SERA 11-06-2024
- Dividend Yield
- LUNG N/A
- SERA N/A
- EPS Growth
- LUNG N/A
- SERA N/A
- EPS
- LUNG N/A
- SERA N/A
- Revenue
- LUNG $76,583,000.00
- SERA $107,000.00
- Revenue This Year
- LUNG $22.73
- SERA N/A
- Revenue Next Year
- LUNG $19.02
- SERA $2,020.00
- P/E Ratio
- LUNG N/A
- SERA N/A
- Revenue Growth
- LUNG 26.26
- SERA N/A
- 52 Week Low
- LUNG $5.46
- SERA $1.56
- 52 Week High
- LUNG $14.84
- SERA $12.36
- Technical
- Relative Strength Index (RSI)
- LUNG 41.60
- SERA 46.26
- Support Level
- LUNG $7.18
- SERA $6.87
- Resistance Level
- LUNG $8.59
- SERA $8.19
- Average True Range (ATR)
- LUNG 0.40
- SERA 0.50
- MACD
- LUNG -0.16
- SERA -0.06
- Stochastic Oscillator
- LUNG 7.74
- SERA 25.00
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services.